Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$9.72 USD
+0.35 (3.72%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $9.38 -0.34 (-3.50%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Avalo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 13 | 55 | 19 | 11 |
Receivables | 0 | 2 | 5 | 4 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 3 | 1 |
Total Current Assets | 8 | 16 | 62 | 26 | 18 |
Net Property & Equipment | 2 | 2 | 3 | 2 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 11 | 14 | 14 | 16 | 17 |
Deposits & Other Assets | 0 | 0 | 1 | 0 | 0 |
Total Assets | 21 | 33 | 80 | 44 | 36 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 6 | 0 | 0 | 0 |
Accounts Payable | 0 | 3 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 13 | 17 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 1 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 4 |
Total Current Liabilities | 5 | 22 | 20 | 15 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 13 | 33 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 9 | 4 | 4 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 14 | 44 | 57 | 19 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 342 | 293 | 285 | 202 | 135 |
Retained Earnings | -335 | -304 | -262 | -178 | -114 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 7 | -11 | 23 | 25 | 21 |
Total Liabilities & Shareholder's Equity | 21 | 33 | 80 | 44 | 36 |
Total Common Equity | 7 | -11 | 23 | 25 | 21 |
Shares Outstanding | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | 9.13 | -10.92 | 23.08 | 24.56 | 21.00 |
Fiscal Year End for Avalo Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 93 | 110 | 7 | 10 | 6 |
Receivables | 0 | 0 | 0 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 1 |
Total Current Assets | 96 | 111 | 8 | 13 | 8 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 11 | 11 | 11 | 14 | 14 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 108 | 124 | 21 | 29 | 24 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 14 |
Accounts Payable | 1 | 1 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 7 | 4 | 5 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 88 | 207 | 0 | 0 | 0 |
Total Current Liabilities | 96 | 216 | 5 | 6 | 22 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 14 | 9 | 8 | 9 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 110 | 225 | 14 | 15 | 31 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 11 | 11 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 344 | 344 | 342 | 341 | 315 |
Retained Earnings | -358 | -456 | -335 | -327 | -322 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -2 | -101 | 7 | 15 | -7 |
Total Liabilities & Shareholder's Equity | 108 | 124 | 21 | 29 | 24 |
Total Common Equity | -14 | -113 | 7 | 15 | -7 |
Shares Outstanding | 1.00 | 1.00 | 0.80 | 0.00 | 0.00 |
Book Value Per Share | -13.61 | -112.55 | 9.13 | 14.70 | -6.97 |